Our laboratory was the first to show that disruption of the JAK/STAT1 signaling pathway in donor T cells prevented development of GVHD in minor Ag-mismatched GVHD and mitigated GVHD in fully-MHC mismatched GVHD (MA) (26). The gene discussed is STAT1; the disease is graft versus host disease.